Janney Montgomery Scott LLC Acquires 12,497 Shares of Boston Scientific Corporation $BSX

Janney Montgomery Scott LLC lifted its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 4.4% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 297,960 shares of the medical equipment provider’s stock after acquiring an additional 12,497 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Boston Scientific were worth $32,004,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Sound Income Strategies LLC raised its holdings in shares of Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 120 shares in the last quarter. 1248 Management LLC purchased a new stake in Boston Scientific in the first quarter worth $26,000. Y.D. More Investments Ltd purchased a new stake in Boston Scientific in the first quarter worth $27,000. Oliver Lagore Vanvalin Investment Group purchased a new stake in Boston Scientific in the second quarter worth $37,000. Finally, Activest Wealth Management grew its stake in Boston Scientific by 6,216.7% in the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 373 shares during the period. Institutional investors own 89.07% of the company’s stock.

Insiders Place Their Bets

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $18,659,923.46. This represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,469,268. This represents a 42.32% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 174,214 shares of company stock valued at $17,972,457. Company insiders own 0.50% of the company’s stock.

Boston Scientific Trading Down 1.9%

NYSE BSX opened at $95.78 on Thursday. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50. The stock has a market cap of $141.91 billion, a P/E ratio of 57.01, a P/E/G ratio of 2.35 and a beta of 0.61. The stock’s fifty day moving average price is $103.30 and its 200-day moving average price is $102.08. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company’s quarterly revenue was up 22.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analysts Set New Price Targets

BSX has been the topic of several recent research reports. Jefferies Financial Group reaffirmed a “hold” rating on shares of Boston Scientific in a research note on Monday, July 21st. Needham & Company LLC reaffirmed a “buy” rating and issued a $121.00 price target on shares of Boston Scientific in a research note on Wednesday. Robert W. Baird upped their price target on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday. Royal Bank Of Canada reissued an “outperform” rating and issued a $125.00 target price on shares of Boston Scientific in a research note on Monday. Finally, Leerink Partners increased their target price on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific presently has an average rating of “Buy” and a consensus target price of $120.67.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.